Vaccination is an important tool in the fight against the COVID-19 pandemic in patients with haematologic malignancies. The paper provides an analysis of the course of breakthrough SARS-CoV-2 infection in a group of vaccinated patients with haematological malignancy and a comparison with a historical cohort of 96 non-vaccinated patients with haematologic malignancies and bone marrow failure syndromes (two patients) in the treatment of COVID-19. A severe or critical course of COVID-19 was significantly less frequent in the group of vaccinated patients (10.2% vs. 31.4%, p = 0.003). The need for hospitalisation due to COVID-19 was significantly lower in vaccinated patients (27.1% vs. 72.6%, p < 0.0001) and the duration of hospitalisation was significantly shorter (10 vs. 14 days, p = 0.045). Vaccinated patients were insignificantly less likely to require oxygen therapy during infection. COVID-19 mortality was significantly higher in non-vaccinated patients (15.6% vs. 5.1%, p = 0.047). The paper demonstrated a significant positive effect of vaccination against COVID-19 on a less severe clinical course of infection, lower need for hospitalisation and mortality. However, the results need to be evaluated even in the context of new antivirals and monoclonal antibodies against SARS-CoV-2 or virus mutations with different biological behaviour.

Department of Haemato Oncology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc 1 P Pavlova 6 77 900 Olomouc Czech Republic

Department of Medical Biophysics Faculty of Medicine and Dentistry Palacky University Olomouc Hněvotínská 3 77 515 Olomouc Czech Republic

Department of Microbiology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Hněvotínská 3 77 515 Olomouc Czech Republic

Zobrazit více v PubMed

Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A., Haagmans B.L., Lauber C., Leontovich A.M., Neuman B.W., et al. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5:536–544. PubMed PMC

Mehta V., Goel S., Kabarriti R., Cole D., Goldfinger M., Acuna-Villaorduna A., Pradhan K., Thota R., Reissman S., Sparano J.A., et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020;10:935–941. doi: 10.1158/2159-8290.CD-20-0516. PubMed DOI PMC

Yigenoglu T.N., Ata N., Altuntas F., Basci S., Dal M.S., Korkmaz S., Namdaroglu S., Basturk A., Hacıbekiroglu T., Dogu M.H., et al. The outcome of COVID-19 in patients with hematological malignancy. J. Med. Virol. 2021;93:1099–1104. doi: 10.1002/jmv.26404. PubMed DOI PMC

Lee L.Y.W., Cazier J.-B., Starkey T., Briggs S.E.W., Arnold R., Bisht V., Booth S., Campton N.A., Cheng V.W.T., Collins G., et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: A prospective cohort study. Lancet Oncol. 2020;21:1309–1316. doi: 10.1016/S1470-2045(20)30442-3. PubMed DOI PMC

Pagano L., Salmanton-García J., Marchesi F., Busca A., Corradini P., Hoenigl M., Klimko N., Koehler P., Pagliuca A., Passamonti F., et al. COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA) J. Hematol Oncol. 2021;14:168. doi: 10.1186/s13045-021-01177-0. PubMed DOI PMC

Vijenthira A., Gong I.Y., Fox T.A., Booth S., Cook G., Fattizzo B., Martín-Moro F., Razanamahery J., Riches J.C., Zwicker J., et al. Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892. doi: 10.1182/blood.2020008824. PubMed DOI PMC

Weinbergerová B., Demel I., Víšek B., Válka J., Čerňan M., Jindra P., Novák J., Stejskal L., Kovácsová F., Kabut T., et al. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients-A Czech multicenter experience. Hematol. Oncol. 2022;40:280–286. doi: 10.1002/hon.2974. PubMed DOI PMC

Thakkar A., Gonzalez-Lugo J.D., Goradia N., Gali R., Shapiro L.C., Pradhan K., Rahman S., Kim S.Y., Ko B., Sica R.A., et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39:1081–1090.e2. doi: 10.1016/j.ccell.2021.06.002. PubMed DOI PMC

Mittelman M., Magen O., Barda N., Dagan N., Oster H.S., Leader A., Balicer R. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 2022;139:1439–1451. doi: 10.1182/blood.2021013768. PubMed DOI PMC

Šušol O., Hájková B., Zelená H., Hájek R. Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres. Br. J. Haematol. 2022;197:302–305. doi: 10.1111/bjh.18073. PubMed DOI

Pagano L., Salmanton-García J., Marchesi F., López-García A., Lamure S., Itri F., Da Silva M.G., Dragonetti G., Falces-Romero I., van Doesum J., et al. COVID-19 in vaccinated adult patients with hematological malignancies: Preliminary results from EPICOVIDEHA. Blood. 2022;139:1588–1592. doi: 10.1182/blood.2021014124. PubMed DOI PMC

Song Q., Bates B., Shao Y.R., Hsu F.-C., Liu F., Madhira V., Mitra A.K., Bergquist T., Kavuluru R., Li X., et al. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients with Cancer: Real-World Evidence From the National COVID Cohort Collaborative. J. Clin. Oncol. 2022;40:1414–1427. doi: 10.1200/JCO.21.02419. PubMed DOI PMC

Štefan M., Dlouhý P., Bezdíčková L. Očkování proti covidu-19. Klin. Mikrobiol. Inf. Lék. 2021;27:49–57. (In Czech) PubMed

WHO Therapeutics and COVID-19: Living Guideline. [(accessed on 10 June 2022)]. Available online: https://apps.who.int/iris/rest/bitstreams/1419047/retrieve.

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. [(accessed on 10 June 2022)]; Available online: https://www.covid19treatmentguidelines.nih.gov.

Doubek M., Mayer J., editors. Léčebné Postupy V Hematologii. Tribun EU; Brno, Czech Republic: 2020. (In Czech)

Čerňan M., Szotkowski T., Obr A., Látal V., Hluší A., Krhovská P., Klementová O., Kolář M., Sauer P., Faber E., et al. COVID-19 in 96 Patients with Hematologic Disease: The First Single-center Experience From the Czech Republic. Clin. Lymphoma Myeloma Leuk. 2021;21:606–612. doi: 10.1016/j.clml.2021.04.016. PubMed DOI PMC

Herishanu Y., Avivi I., Aharon A., Shefer G., Levi S., Bronstein Y., Morales M., Ziv-Baran T., Arbel Y.S., Scarfò L., et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–3173. doi: 10.1182/blood.2021011568. PubMed DOI PMC

Greenberger L.M., Saltzman L.A., Senefeld J.W., Johnson P.W., DeGennaro L.J., Nichols G.L. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39:1031–1033. doi: 10.1016/j.ccell.2021.07.012. PubMed DOI PMC

Bange E.M., Han N.A., Wileyto P., Kim J.Y., Gouma S., Robinson J., Greenplate A.R., Hwee M.A., Porterfield F., Owoyemi O., et al. CD8 + T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 2021;27:1280–1289. doi: 10.1038/s41591-021-01386-7. PubMed DOI PMC

Tenbusch M., Schumacher S., Vogel E., Priller A., Held J., Steininger P., Beileke S., Irrgang P., Brockhoff R., Salmanton-García J., et al. Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect. Dis. 2021;21:1212–1213. doi: 10.1016/S1473-3099(21)00420-5. PubMed DOI PMC

Nyberg T., Ferguson N.M., Nash S.G., Webster H.H., Flaxman S., Andrews N., Hinsley W., Bernal J.L., Kall M., Abbott S., et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study. Lancet. 2022;399:1303–1312. doi: 10.1016/S0140-6736(22)00462-7. PubMed DOI PMC

Twohig K.A., Nyberg T., Zaidi A., Thelwall S., Sinnathamby M.A., Aliabadi S., Seaman S.R., Harris R.J., Hope R., Lopez-Bernal J., et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: A cohort study. Lancet Infect. Dis. 2022;22:35–42. doi: 10.1016/S1473-3099(21)00475-8. PubMed DOI PMC